TY - JOUR AU - Coiffier, B. AU - Lepretre, S. AU - Pedersen, L. M. AU - Gadeberg, O. AU - Fredriksen, H. AU - Oers, M. H. PY - 2008 DA - 2008// TI - Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study JO - Blood VL - 111 UR - https://doi.org/10.1182/blood-2007-09-111781 DO - 10.1182/blood-2007-09-111781 ID - Coiffier2008 ER - TY - JOUR AU - Freedman, B. PY - 1987 DA - 1987// TI - Equipoise and the ethics of clinical research JO - N Engl J Med VL - 317 UR - https://doi.org/10.1056/NEJM198707163170304 DO - 10.1056/NEJM198707163170304 ID - Freedman1987 ER - TY - STD TI - Center for drug evaluation and research. ofatumumab: clinical review and evaluation. 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125326s000_MedR.pdf. Accessed 12 Jan 2016. UR - http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125326s000_MedR.pdf ID - ref3 ER - TY - STD TI - US. Food and Drug Administration (FDA). Ofatumumab. 2009. http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm188221.htm. Accessed 29 Apr 2014. UR - http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm188221.htm ID - ref4 ER - TY - STD TI - European Medicines Agency (EMA). Public summary of opinion on orphan designation ofatumumab for the treatment of chronic lymphocytic leukemia. 2010. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000468.jsp&mid=WC0b01ac058001d12b. Accessed 29 Apr 2014. UR - http://www.ema.europa.eu/ema/index.jsp%3fcurl%3dpages/medicines/human/orphans/2009/11/human_orphan_000468.jsp%26mid%3dWC0b01ac058001d12b ID - ref5 ER - TY - STD TI - ClinicalTrials.gov. Ofatumumab + chlorambucil vs chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia (complement 1) [NCT00748189]. 2008. http://clinicaltrials.gov/ct2/show/NCT00748189?term=ofatumumab+chronic+lymphocytic&rank=14. Accessed 29 Apr 2014. UR - http://clinicaltrials.gov/ct2/show/NCT00748189%3fterm%3dofatumumab%2bchronic%2blymphocytic%26rank%3d14 ID - ref6 ER - TY - JOUR AU - Sutton, A. AU - Ades, A. E. AU - Cooper, N. AU - Abrams, K. PY - 2008 DA - 2008// TI - Use of indirect and mixed treatment comparisons for technology assessment JO - Pharmacoeconomics VL - 26 UR - https://doi.org/10.2165/00019053-200826090-00006 DO - 10.2165/00019053-200826090-00006 ID - Sutton2008 ER - TY - STD TI - National Institute for Health and Clinical Excellence (NICE). Final appraisal determination: imatinib for chronic myeloid leukemia. 2003. https://www.nice.org.uk/guidance/ta70/documents/final-appraisal-determination-imatinib-for-chronic-myeloid-leukemia2. Accessed 29 Apr 2014. UR - https://www.nice.org.uk/guidance/ta70/documents/final-appraisal-determination-imatinib-for-chronic-myeloid-leukemia2 ID - ref8 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. 2015. http://www.nicedsu.org.uk/TSD17%20-%20DSU%20Observational%20data%20FINAL.pdf. Accessed 12 Jan 2017. UR - http://www.nicedsu.org.uk/TSD17%20-%20DSU%20Observational%20data%20FINAL.pdf ID - ref9 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016. http://www.nicedsu.org.uk/TSD18%20Population%20adjustment%20TSD%20-%20FINAL.pdf. Accessed 12 Jan 2017. UR - http://www.nicedsu.org.uk/TSD18%20Population%20adjustment%20TSD%20-%20FINAL.pdf ID - ref10 ER - TY - JOUR AU - Tam, C. S. AU - O’Brien, S. AU - Lerner, S. AU - Khouri, I. AU - Ferrajoli, A. AU - Faderl, S. PY - 2007 DA - 2007// TI - The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy JO - Leuk Lymphoma VL - 48 UR - https://doi.org/10.1080/10428190701573257 DO - 10.1080/10428190701573257 ID - Tam2007 ER - TY - JOUR AU - Fraser, G. AU - Smith, C. A. AU - Imrie, K. AU - Meyer, R. PY - 2007 DA - 2007// TI - Alemtuzumab in chronic lymphocytic leukemia JO - Curr Oncol. VL - 14 UR - https://doi.org/10.3747/co.2007.118 DO - 10.3747/co.2007.118 ID - Fraser2007 ER - TY - JOUR AU - Lemery, S. J. AU - Zhang, J. AU - Rothmann, M. D. AU - Yang, J. AU - Earp, J. AU - Zhao, H. PY - 2010 DA - 2010// TI - US Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-0570 DO - 10.1158/1078-0432.CCR-10-0570 ID - Lemery2010 ER - TY - JOUR AU - Cheson, B. D. AU - Bennett, J. M. AU - Grever, M. AU - Kay, N. AU - Keating, M. J. AU - O’Brien, S. PY - 1996 DA - 1996// TI - National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment JO - Blood VL - 87 ID - Cheson1996 ER - TY - JOUR AU - Wierda, W. G. AU - Kipps, T. J. AU - Mayer, J. AU - Stilgenbauer, S. AU - Williams, C. D. AU - Hellmann, A. PY - 2010 DA - 2010// TI - Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.3187 DO - 10.1200/JCO.2009.25.3187 ID - Wierda2010 ER - TY - STD TI - Curtis L. Unit costs of health and social care 2009. 2009. http://www.pssru.ac.uk. Accessed 29 Apr 2014. UR - http://www.pssru.ac.uk ID - ref16 ER - TY - STD TI - National Health Service (NHS). Reference costs 2008–2009. 2010. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591. Accessed 29 Apr 2014. UR - http://webarchive.nationalarchives.gov.uk/%2b/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 ID - ref17 ER - TY - STD TI - Ferguson J, Tolley K, Gilmour L, Priaulx J. Health state preference study mapping the change over the course of the disease process in chronic lymphocytic leukemia (CLL) ISPOR 11th Annual European Congress. Athens. 8–11 November 2008. Poster PCN79. ID - ref18 ER - TY - STD TI - National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 29 Apr 2014. UR - http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf ID - ref19 ER - TY - STD TI - HM Treasury. The green book: appraisal and evaluation in central government. 2009. https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-governent. Accessed 29 Apr 2014. UR - https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-governent ID - ref20 ER - TY - STD TI - National Institute for Health and Clinical Excellence (NICE). TA202: ofatumumab for the treatment of chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. 2010. http://www.nice.org.uk/nicemedia/live/13240/51314/51314.pdf. Accessed 29 Apr 2014. UR - http://www.nice.org.uk/nicemedia/live/13240/51314/51314.pdf ID - ref21 ER - TY - JOUR AU - Husereau, D. AU - Drummond, M. AU - Petrou, S. AU - Carswell, C. AU - Moher, D. AU - Greenberg, D. PY - 2013 DA - 2013// TI - Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force JO - Value Health VL - 16 UR - https://doi.org/10.1016/j.jval.2013.02.002 DO - 10.1016/j.jval.2013.02.002 ID - Husereau2013 ER - TY - STD TI - F. Hoffmann-La Roche Ltd. Roche Statement: another milestone in clinical data sharing: new system for requesting analyzable patient-level data begins on 1 January 2014. 2014. http://www.roche.com/media/med-stat-2014-01-02.htm. Accessed 29 Apr 2014. UR - http://www.roche.com/media/med-stat-2014-01-02.htm ID - ref23 ER -